Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Clinical trial NCT00186628 · COMPLETED

Trial details

NCT number: NCT00186628
Sponsor: Stanford University
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Leukemia, Mast-Cell Mantle-cell Lymphoma

Start date: 2005-06-01
Primary completion: 2010-11-01
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.